Last week, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced data from a Phase II study of its lead development asset Anabasum. The data appeared...
Keep Reading →
April 4 - News, Stock Analysis - Comments
The cannabis space has been one of the most closely watched, and the most active, sectors across the last twelve months. The Viridian Cannabis Stock Index...
Keep Reading →
March 22 - News, Stock Analysis - Comments
AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S. Food and Drug Administration for ZS...
Keep Reading →
March 21 - News, Stock Analysis - Comments
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the...
Keep Reading →
March 21 - News, Stock Analysis - Comments
In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million...
Keep Reading →
March 20 - News, Stock Analysis - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has unveiled the authorized generic version of Minastrin, an oral contraceptive that is combined...
Keep Reading →
March 20 - News, Stock Analysis - Comments
At the end of last week, Amgen, Inc. (NASDAQ:AMGN) announced some data from its large-scale trial of its cardiovascular risk asset Repatha. The drug first...
Keep Reading →
March 20 - News, Stock Analysis - Comments
Positive results for the Phase III study meant to test the experiences of patients using the eye insert known as Dextenza to relieve pain in a post-surgical...
Keep Reading →
March 17 - News, Stock Analysis - Comments
Plans to start a new Phase II study of SER-109, branded ECOSPOR III, have been announced by Seres Therapeutics Inc (NASDAQ:MCRB). The drug is meant to...
Keep Reading →
March 17 - News, Stock Analysis - Comments
Here’s a look at some of the week’s biggest movers in biotech, what’s moving them, and where we expect things to go early next week and beyond....
Keep Reading →
March 17 - Market Movers, News, Stock Analysis - Comments
The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic PLC. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug...
Keep Reading →
March 17 - News, Stock Analysis - Comments
Reports indicate that there are a number of plaintiffs filing lawsuits against Merck & Co., Inc. (NYSE:MRK) claiming that its shingles vaccine, Zostavax...
Keep Reading →
March 16 - News, Stock Analysis - Comments
After recently getting the approval of the U.S. Food and Drug Administration, Novartis AG (ADR) (NYSE:NVS) has announced that a flexible pricing system...
Keep Reading →
March 16 - News, Stock Analysis - Comments
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression. AstraZeneca...
Keep Reading →
March 16 - News, Stock Analysis - Comments
After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has...
Keep Reading →
March 16 - News, Stock Analysis - Comments
In the Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) public offering, common shares totaling 22,300,000 will be offered at $6.75 a share. The biopharmaceutical...
Keep Reading →
March 15 - News, Stock Analysis - Comments
It’s been a big week for PARP inhibitors. AstraZeneca PLC (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza...
Keep Reading →
March 15 - News, Stock Analysis - Comments
In its efforts to contribute to a generation that is tobacco-free, CVS Health Corp (NYSE:CVS) has devoted $50 million for a five-year program. The drug...
Keep Reading →
March 14 - News, Stock Analysis - Comments
AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially...
Keep Reading →
March 14 - News, Stock Analysis - Comments
It’s been a busy quarter in the biotechnology space, but it’s not over yet. This month promises to bring with it a flurry of end of quarter catalysts...
Keep Reading →
March 14 - News, Stock Analysis - Comments
Pershing Square Capital Management, managed by Bill Ackman, sold its entire stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Monday. The investor...
Keep Reading →
March 14 - Hedge Funds, News, Stock Analysis - Comments
Allergan plc Ordinary Shares (NYSE:AGN) has announced that an application to have new clinical data for Vraylar evaluated has been accepted by the Food...
Keep Reading →
March 13 - News, Stock Analysis - Comments
The Centers for Medicare & Medicaid Services (CMS) has granted approval to the Micra Transcatheter pacemaker (Micra TPS) that is manufactured by Medtronic...
Keep Reading →
March 13 - News, Stock Analysis - Comments
Every so often, a biotech company takes a hit on some news that seems negative, and at first glance is, but is likely only temporary in terms of impact...
Keep Reading →
March 13 - News, Stock Analysis - Comments
A court in Germany has ruled that patents held by Boston Scientific Corporation (NYSE:BSX) were infringed upon by Edwards Lifesciences Corp (NYSE:EW)....
Keep Reading →
March 10 - News, Stock Analysis - Comments
Yet again we’ve had a pretty busy week in the biotech space. Macro forces are coming in to play, and combined with what proved a busy release calendar...
Keep Reading →
March 10 - Market Movers, News, Stock Analysis - Comments
CVS Health Corp (NYSE:CVS) has announced that patients in four more states who don’t have an individual prescription will be allowed to get naloxone...
Keep Reading →
March 10 - News, Stock Analysis - Comments
Global Blood Therapeutics Inc (NASDAQ:GBT) is spiking towards the end of the week on the suggestion that it might be an acquisition target for a big pharma...
Keep Reading →
March 10 - News, Stock Analysis - Comments
Reports allege that Pfizer Inc. (NYSE:PFE) is holding talks with Lee County officials as it considers investing $100 million to expand a plant located...
Keep Reading →
March 8 - News, Stock Analysis - Comments
A Phase III study has shown that GP2017, which is manufactured by Sandoz, a unit of Novartis AG (ADR) (NYSE:NVS), has shown positive results as a Humira...
Keep Reading →
March 8 - News, Stock Analysis - Comments
Last week we looked at development stage biotechnology company Aurinia Pharmaceuticals Inc (NASDAQ:AUPH). At the time of our coverage, the company had...
Keep Reading →
March 8 - News, Stock Analysis - Comments
The U.S. Food and Drug Administration (FDA) has acknowledged the filing for review of three New Drug Applications (NDAs) from Merck & Co., Inc. (NYSE...
Keep Reading →
March 8 - News, Stock Analysis - Comments
Detailed results from the IXORA-S study have revealed that Taltz (ixekizumab) has superior efficacy compared to Stelara (ustekinumab). According to Eli...
Keep Reading →
March 8 - News, Stock Analysis - Comments
TG Therapeutics Inc (NASDAQ:TGTX) is a big runner this week, with the company up close t 90% during Monday’s session alone out of the US. Chances are...
Keep Reading →
March 7 - News, Stock Analysis - Comments
The prices of Perrigo Company plc Ordinary Shares (NYSE:PRGO) drugs used in skin treatments is being examined by law enforcement authorities. This is...
Keep Reading →
March 6 - News, Stock Analysis - Comments
Two patents that AbbVie Inc (NYSE:ABBV) held on Humira, a treatment for arthritis, have been invalidated by an English court. The ruling was in favor...
Keep Reading →
March 6 - News, Stock Analysis - Comments
Last week we saw plenty of volatility across the healthcare and biotechnology sectors, driven both by macro and micro factors. We’re expecting much...
Keep Reading →
March 6 - News, Stock Analysis - Comments
Novartis AG (ADR) (NYSE:NVS) has been fined approximately $174,000 in South Korea after the company was found guilty of bribing physicians in order to...
Keep Reading →
March 3 - News, Stock Analysis - Comments
Epic’s EHR systems has been selected for use by CVS Health Corp (NYSE:CVS) in its programs for care management. The new record system is expected to...
Keep Reading →
March 3 - News, Stock Analysis - Comments
The end of the week is upon us, and it’s been a bit of a wild ride in the biotech space. Macro forces have come into play from an industry wide sentiment...
Keep Reading →
March 3 - News, Stock Analysis - Comments
The Food and Drug Administration has granted final approval to Axiron Topical Solution, a drug manufactured by Perrigo Company plc Ordinary Shares (NYSE...
Keep Reading →
March 2 - News, Stock Analysis - Comments
In most cases, equity financings below market are bad news for shareholders. There are exceptions though. Corbus Pharmaceuticals Holdings Inc (NASDAQ:...
Keep Reading →
March 2 - News, Stock Analysis - Comments
The number of states accusing Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Mylan N.V. (NASDAQ:MYL) for price collusion have risen as the list...
Keep Reading →
March 2 - News, Stock Analysis - Comments
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S. Food and Drug Administration...
Keep Reading →
March 2 - News, Stock Analysis - Comments
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a real winner towards the end of this week, on a fresh batch of data from its lead lupus study. The data...
Keep Reading →
March 2 - News, Stock Analysis - Comments
The royalty stream that Perrigo Company plc Ordinary Shares (NYSE:PRGO) used to get from Tysabri has been sold to Royalty Pharma. Both companies are based...
Keep Reading →
March 1 - News, Stock Analysis - Comments
Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these...
Keep Reading →
March 1 - News, Stock Analysis - Comments
An application for a new drug by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been accepted by the Food and Drug Administration. Teva’s...
Keep Reading →
March 1 - News, Stock Analysis - Comments
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has caught our attention in the biotech space as being a company that has had a bit of a strange start to...
Keep Reading →
March 1 - News, Stock Analysis - Comments
In new guidelines, Heron Therapeutics Inc (NASDAQ:HRTX) has announced that Sustol will be included as an extended-release injection. A recommendation...
Keep Reading →
March 1 - News, Stock Analysis - Comments
